| Literature DB >> 21857934 |
Ji-Lin Wang1, Yan-Wei Lin, Hui-Min Chen, Xuan Kong, Hua Xiong, Nan Shen, Jie Hong, Jing-Yuan Fang.
Abstract
BACKGROUND AND AIM: Calcium has been proposed as a mediator of the chemoprevention of colorectal cancer (CRC), but the comprehensive mechanism underlying this preventive effect is not yet clear. Hence, we conducted this study to evaluate the possible roles and mechanisms of calcium-mediated prevention of CRC induced by 1,2-dimethylhydrazine (DMH) in mice.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21857934 PMCID: PMC3157344 DOI: 10.1371/journal.pone.0022566
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primer sequence.
| Gene name | Forward sequence | Reverse sequence | Product length |
| S100a9 |
|
| 169 |
| Mmp10 |
|
| 142 |
| Defa20 |
|
| 128 |
| Ptgs2 |
|
| 153 |
| Per3 |
|
| 246 |
| Tef |
|
| 122 |
| Rnf152 |
|
| 106 |
| Prdx6 |
|
| 120 |
| 18S rRNA |
|
| 150 |
Figure 1Main results of the animal experiment.
A. Observation of tumors in the large bowel of mice after sacrifice at 24 weeks. B (×200) and C (×400). Most of the tumors were confirmed as adenocarcinomas by pathological examination. D. Tumor incidence among the 4 groups. E. Tumor number/mice among the 4 groups. F. Maximum tumor diameter among the 4 groups (Control: Control group, received normal feed and injection of normal sodium for 20 weeks; DMH: DMH group, received normal feed and injection of DMH for 20 weeks; DMH+Calcium group: received high-calcium feed and injection of DMH for 20 weeks; Calcium group: received high-calcium feed and injection of normal sodium for 20 weeks). * P value<0.05 between DMH+Calcium group and DMH group.
List of the most differentially expressed genes whose changes due to DMH treatment could be reversed by diatery calcium.
| Accession number | Gene symbol | Gene Description | Fold change | P value |
| NM_007847 | Defa-rs2 | defensin, alpha, related sequence 2 | −9.88 | 1.93E-04 |
| NM_009114 | S100a9 | S100 calcium binding protein A9 | −9.58 | 4.25E-05 |
| NM_019471 | Mmp10 | matrix metallopeptidase 10 | −9.47 | 7.67E-07 |
| NM_008607 | Mmp13 | matrix metallopeptidase 13 | −9.10 | 1.48E-04 |
| NM_183268 | Defa20 | defensin, alpha, 20 | −8.16 | 1.20E-04 |
| NM_010810 | Mmp7 | matrix metallopeptidase 7 | −7.07 | 0.00411071 |
| EU817850 | Gm5222 | monoclonal antibody 1D6 immunoglobulin light chain variable region | −6.98 | 1.99E-05 |
| NM_008764 | Tnfrsf11b | tumor necrosis factor receptor superfamily, member 11b | −5.98 | 0.01292794 |
| NM_011915 | Wif1 | Wnt inhibitory factor 1 | −5.79 | 0.00447852 |
| NM_001174099 | Krt36 | keratin 36 | −5.79 | 2.75E-04 |
| NM_009263 | Spp1 | secreted phosphoprotein 1 | −5.40 | 1.31E-04 |
| NM_175391 | Apol7c | apolipoprotein L 7c | −4.93 | 5.03E-07 |
| NM_007969 | Expi | extracellular proteinase inhibitor | −4.78 | 3.00E-02 |
| NM_008256 | Hmgcs2 | 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 | −4.62 | 9.86E-06 |
| NM_010743 | Il1rl1 | interleukin 1 receptor-like 1 | −4.38 | 1.28E-05 |
| NM_026414 | Asprv1 | aspartic peptidase, retroviral-like 1 | −4.38 | 2.82E-05 |
| NM_007449 | Ang2 | angiogenin, ribonuclease A family, member 2 | −4.34 | 0.04452419 |
| NM_053080 | Aldh1a3 | aldehyde dehydrogenase family 1, subfamily A3 | −4.11 | 0.01939012 |
| NM_007440 | Alox12 | arachidonate 12-lipoxygenase | −4.03 | 0.02319294 |
| NM_001142959 | Bcl2l15 | BCLl2-like 15,transcript variant 1 | −3.95 | 5.27E-04 |
| NM_016958 | Krt14 | keratin 14 | −3.81 | 0.00713059 |
| NM_007753 | Cpa3 | carboxypeptidase A3 | −3.74 | 3.03E-05 |
| NM_008939 | Prss12 | protease, serine, 12 neurotrypsin | −3.65 | 0.04354441 |
| NM_011280 | Trim10 | tripartite motif-containing 10 | −3.58 | 3.46E-06 |
| NM_001082531 | Pla2g2a | phospholipase A2, group IIA | −3.50 | 8.61E-04 |
| NM_021285 | Myl1 | myosin, light polypeptide 1 | −3.31 | 9.72E-04 |
| NM_011067 | Per3 | period homolog 3 | 3.16 | 2.08E-05 |
| NM_153484 | Tef | thyrotroph embryonic factor | 2.98 | 1.26E-05 |
| NM_011198 | Ptgs2 | prostaglandin-endoperoxide synthase 2 | −2.87 | 1.53E-04 |
| AK081980 | Prdx6 | 16 days embryo head cDNA, product:peroxiredoxin 5 | 2.87 | 0.01674954 |
| NM_178779 | Rnf152 | ring finger protein 152 | 2.63 | 0.0028878 |
Fold changs and P values are the results comparing DMH+Calcium group and DMH group.
Figure 2Validation of differentially expressed genes by real-time polymerase chain reaction.
We used 18 s rRNA as an internal control. Relative mRNA expression was calculated according to the 2−ΔΔT method. Data are the mean of 10 samples ± SD. Control, gene expression level in the normal colon tissue of mice in the Control group; DMH, gene expression level in the non-tumor colon tissue of mice in the DMH group; DMH+Calcium, gene expression level in the non-tumor colon tissue of mice in the DMH+Calcium group; Calcium, gene expression in the non-tumor colon tissue of mice in the Calcium group. * P value<0.05 between DMH+Calcium group and DMH group; § P value<0.05 between Calcium group and Control group.
The most enrichment pathways by KEGG.
| Pathway ID | Pathway name | Selection Count | Count | Enrichment |
|
| ||||
| mmu04310 | Wnt signaling pathway | 11 | 148 | 5.123285 |
| mmu05140 | Leishmaniasis | 6 | 67 | 3.468583 |
| mmu04110 | Cell cycle | 8 | 127 | 3.383628 |
| mmu04370 | VEGF signaling pathway | 5 | 76 | 2.378304 |
| mmu04010 | MAPK signaling pathway | 10 | 272 | 2.299372 |
| mmu04114 | Oocyte meiosis | 6 | 114 | 2.277315 |
| mmu04664 | Fc epsilon RI signaling pathway | 5 | 81 | 2.260629 |
| mmu04350 | TGF-beta signaling pathway | 5 | 84 | 2.194259 |
| mmu05222 | Small cell lung cancer | 5 | 84 | 2.194259 |
| mmu04640 | Hematopoietic cell lineage | 5 | 85 | 2.172789 |
| mmu00590 | Arachidonic acid metabolism | 5 | 86 | 2.151633 |
| mmu04012 | ErbB signaling pathway | 5 | 88 | 2.110233 |
| mmu00650 | Butanoate metabolism | 3 | 30 | 2.084872 |
| mmu05216 | Thyroid cancer | 3 | 30 | 2.084872 |
|
| ||||
| mmu00982 | Drug metabolism - cytochrome P450 | 8 | 85 | 7.972006 |
| mmu04710 | Circadian rhythm - mammal | 4 | 22 | 5.391566 |
| mmu00591 | Linoleic acid metabolism | 3 | 45 | 2.827674 |
| mmu00910 | Nitrogen metabolism | 2 | 23 | 2.231527 |
| mmu00980 | Metabolism of xenobiotics by cytochrome P450 | 3 | 75 | 2.197296 |
| mmu00830 | Retinol metabolism | 3 | 78 | 2.150205 |
| mmu03320 | PPAR signaling pathway | 3 | 81 | 2.105092 |
“SelectionCounts” stands for the Count of the DE genes' entities directly associated with the listed PathwayID;
“Count” stands for the count of the chosen background population genes' entities associated with the listed PathwayID;
“Enrichment_Score” stands for the Enrichment Score value of the PathwayID, it equals “−log10(Pvalue)”.
Figure 3Expression of β-catenin in the non-tumor colorectal mucosa in the 4 groups determined by immunohistochemistry.
Control, Control group; DMH, DMH group; DMH+Calcium, DMH+Calcium group; Calcium, Calcium group.
Partial list of the hub genes.
| Name | Total No.of targeted genes | No.of overlap genes | Percent overlap | Gene set seed | P value |
| Expression Targets of Jun/Fos | 542 | 68 | 12% | Jun/Fos | 1.55E-08 |
| Expression Targets of PKA | 369 | 52 | 14% | PKA | 2.03E-08 |
| Expression Targets of EGF | 504 | 64 | 12% | EGF | 2.71E-08 |
| Expression Targets of FOXM1 | 108 | 24 | 22% | FOXM1 | 4.04E-08 |
| Expression Targets of TP53 | 538 | 65 | 12% | TP53 | 1.41E-07 |
| Expression Targets of MYOCD | 36 | 13 | 35% | MYOCD | 1.66E-07 |
| Expression Targets of NF-kB | 742 | 76 | 10% | NF-kB | 8.28E-06 |
| Expression Targets of TNF | 900 | 87 | 9% | TNF | 1.69E-05 |
Figure 4Potential hub genes derived from Pathway studio software.
The differentially expressed genes regulated by the 2 hub genes (A,FoxM1;B, NF-κB) are displayed in form of a network diagram. Green or red coloring, sequences that are downregulated or upregulated in the DMH+Calcium group compared with the DMH group, respectively. The intensity of the color is proportional to the extent of change.